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FPIN's Clinical Inquiries 
Antiviral Agents for Pregnant Women with Genital Herpes 
Clinical Question 
Do antiviral medications prevent perinatal transmission of genital herpes to neonates? 
Evidence-Based Answer 
There is no evidence that the use of antiviral agents in women who are pregnant and have a 
history of genital herpes prevents perinatal transmission of herpes simplex virus (HSV) to 
neonates. [Strength of recommendation: A, based on multiple systematic reviews] 
However, treatment with antivirals during the last month of pregnancy does reduce the rate of 
HSV outbreaks in pregnant women and the resultant need for cesarean delivery. [Strength of 
recommendation: A, based on multiple systematic reviews] 
Evidence Summary 
Neonatal herpes infection is the major consequence of maternal HSV. Fortunately, the 
transmission rate is quite low (less than 1 percent) for nonprimary HSV outbreaks. This poses a 
problem in assessing the effectiveness of antivirals for preventing this serious illness, because 
even a large meta-analysis is underpowered in addressing this issue. 
One systematic review and one meta-analysis reviewed a total of five randomized controlled 
trials. Both reviews were of good quality. The trials involved pregnant women with recurrent and 
first-episode HSV infections. In each study, women were randomized to either acyclovir 
(Zovirax) or placebo for HSV prophylaxis beginning at 36 weeks' gestation. The dosages of 
acyclovir ranged from 800 to 1,200 mg per day. Acyclovir was the only antiviral agent evaluated 
in either study. 
The aggregate data involved nearly 800 patients. There were no reported cases of neonatal HSV 
infection in either the treatment or placebo groups. There was good evidence that prophylaxis 
with antiviral agents during the last month of pregnancy was effective in reducing the rate of 
HSV outbreaks during the perinatal period in mothers with HSV infections (15 of 424 in the 
acyclovir group versus 58 of 375 in the placebo group had HSV outbreaks during the perinatal 
period, absolute risk reduction [ARR] = 11%, number needed to treat [NNT] = 9). Presumably 
because of the significant reduction in HSV recurrences with antiviral prophylaxis, the total 
cesarean delivery rate was significantly lower in the treatment group (17 versus 26 percent, ARR 
= 9%, NNT = 11) as well as the rate of cesarean delivery for HSV recurrence (4 versus 15 
percent, ARR = 11%, NNT = 9). Treatment also eliminated the risk of laboratory-detected HSV 
infection at delivery (0 versus 5 percent, ARR = 5%, NNT = 20). 
Recommendations from Others 
The 2001 National Guideline for the Management of Genital Herpes, published by the 
Association for Genitourinary Medicine and the Medical Society for the Study of Venereal 
Disease, recommends the use of continuous acyclovir during the last month of pregnancy as a 
treatment option in women with recurrent genital herpes.4 The American College of 
Obstetricians and Gynecologists (ACOG) recommends that women with a first episode of HSV 
during any stage of pregnancy should be treated with a seven- to 14-day course of an antiviral 
agent. ACOG also notes that for women at risk of recurrent HSV, initiation of antiviral therapy 
during the last month of pregnancy may be warranted. 
Clinical Commentary 
With the evidence that antiviral treatment reduces the rates of maternal HSV outbreaks in the 
perinatal period and subsequent cesarean deliveries, one could argue that maternal morbidity and 
costs are decreased with treatment. A cheap, safe medicine (acyclovir) and a small NNT of 93 
add credence to this argument. Despite the lack of data regarding the outcome of neonatal HSV 
infection, the sample size required is so large that such a study may never be performed. Thus, 
acyclovir use for the prevention of perinatal HSV in the final month of pregnancy appears to be a 
reasonable treatment option 
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